AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
A DeepMind spinoff has developed AI-designed drugs that are now set to enter human trials. These drugs represent a novel approach to utilizing artificial intelligence in drug development.
More in Research
New benchmark confirms AI video generators look stunning but still can't reason about the world
New benchmarks show that AI video generators produce stunning visuals but struggle with reasoning about real-world contexts. This gap highlights the need for further advancements in AI understanding to improve practical applications.
Researchers train AI model that hits near-full performance with just 12.5 percent of its experts
Researchers trained an AI model that achieves near-full performance using only 12.5% of its experts. This efficiency could lead to faster training times and reduced resource costs for AI development.
Western Gull, Rock Pigeon
Simon Willison just shared insights on the Western Gull and Rock Pigeon. He highlights their unique behaviors and adaptations in urban environments.
The promises and pitfalls of personalized health
Researchers are exploring how personalized health solutions can improve patient outcomes through tailored treatments. This shift could lead to more effective healthcare strategies and better patient engagement.
